The UK and US have secured a key commercial pact that will keep no tariffs on UK drug shipments going into the US market.
The Terms of the Deal
As part of the deal, the UK has committed to raise expenditure on medicines through the public health system. This pledge guarantees that import taxes on these vital exports will remain at zero for a period of the next three years.
This agreement follows earlier statements to hike tariffs on patented pharmaceutical imports, with figures mentioned as high as 100%.
"This agreement with the Britain strengthens the global environment for new treatments and introduces much-needed fairness to U.S.–U.K. drug exports," an announcement said.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's largest goods shipped to the America, which is easily the primary buyer for major companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of the third quarter, the UK sold medicines worth billions to the US. This value accounted for a significant portion of total UK exports in that span.
"This deal safeguards jobs, stimulates investment and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at fifteen percent. Previously, rebates were more than 20%.
Industry Background
The pact follows a long-running dispute between the sector and the UK government over drug pricing and regulatory access.
These tensions were intensified by arguments that American consumers were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar expansions have been pledged toward US facilities.
A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had declined as a proportion of its overall budget over the past decade.
